Oklahoma State University Medical Center/ Family Medicine Department Anticonvulsant Hypersensitivity Syndrome (AHS)

Danielle Manship, OMS III, Martina Swinger, D.O., Andrew Crow, D.O., Jenny Alexopulos, D.O.

Overview of AHS

Anticonvulsant Hypersensitivity Syndrome is a rare, drug induced, multiorgan syndrome characterized by fever, rash, eosinophilia, and other multiorgan abnormalities.¹ This syndrome is most commonly associated with aromatic antiepileptic drugs such as phenytoin, phenobarbital, and carbamazepine.²

Case Report

Chief Complaint

Pruritic Rash

History of Present Illness

81 year-old female presented with pruritic rash onset 2 weeks ago. The rash spread from neck distally (Figure 1 and Figure 2). She was treated at Urgent Care 3 days prior to arrival who suggested hyperglycemia was the etiology of her rash, and increased her dose of Metformin. Her rash acutely worsened after the dose increase.

Past Medical History

Type 2 Diabetes Mellitus

Past Surgical History

Cranial tumor resection in 1993

Home Medications

Metformin 500mg PO QD Phenytoin 100mg PO TID

Physical Exam

Vitals: 184/93, HR 124 bpm, T 36.8C, RR 18, O2 sat 99% on room air. Skin: Diffuse, pruritic, confluent, maculopapular rash with leather-like texture changes involving the entire body including palms and soles. No mucosal involvement. Negative Nikolsky sign.

| | Hospital Course Timeline |
|-----------------------|--|
| Admission | Admitted to general medical floor in stable condition All home medications held |
| | |
| Day 1 | 1mg/kg prednisone PO initiated Punch biopsy obtained of right thigh |
| | |
| Day 2 | Additional punch biopsy of right deltoid obtained Rash 25% improved |
| | |
| Hospital Follow Up | Pathology report reviewed confirming AHS Pathology reports confirmed Anticonvulsant Hypersensitivity Syndrome |
| (Day 4) | |





Figures 1 and 2: Maculopapular rash with desquamation; Day 1

Laboratory Studies

| VBC | 8.2 |
|---------|---------|
| RBC | 4.53 |
| lgb | 14.2 |
| lct | 42.2 |
| ЛСЛ | 93.2 |
| ЛСН | 31.3 |
| ЛСНС | 33.6 |
| RDW | 11.2 |
| Plt | 197. |
| ЛРV | 7.1 (L) |
| leut % | 77.0 |
| .ymph % | 15.0 |
| Nono % | 6.0 |
| os % | 2.0 |
| Baso % | 0.0 |
| leut# | 6.3 |
| .ymph # | 1.2 |
| √ono # | 0.5 |
| os # | 0.2 |
| Baso # | 0.0 |

| ESR |
|---------------|
| CRP |
| Na |
| Κ |
| Cl |
| Bicarb |
| AG |
| BUN |
| Cr |
| GFR |
| Glucose |
| Ca |
| T Bili |
| AST |
| ALT |
| Alk Phos |
| Total Protein |
| Albumin |
| PT |

INR



Figure 4: Normal skin biopsy.



RESULTS

Figure 3: Outpatient clinic follow up appointment; Day 4

| 13 (L) | Urine Clean Ca | atch |
|----------|----------------|-------------|
| 4.97 (H) | Urine Color | Yellow |
| 135 | Urine pH | 6.0 |
| 4.1 | Spec Gravity | 1.010 |
| 97 (L) | Ur Protein | NEGATIVE |
| 25 | Ur Glucose | NEGATIVE |
| 13 | Ur Ketones | NEGATIVE |
| 13 | Ur Blood | NEGATIVE |
| 0.73 | Ur Nitrite | NEGATIVE |
| 76 | Ur Bili | NEGATIVE |
| 125 (H) | Ur Urobili | NEGATIVE |
| 9.4 | Ur Leuk Est | TRACE (H) |
| 0.5 | Ur RBC | NONE SEEN |
| 20 | Ur WBC | 0-2 |
| 22 | Ur Squa Ep | 0-2 |
| 128 | Ur Bacteria | RARE |
| 7.0 | Ur Cx | Mixed Flora |
| 3.9 | Blood Cx x2 | NEGATIVE |
| 14.2 | | |



Figures 5, and 6: Patient's skin biopsy showing Drug Induced Hypersensitivity Reaction.

Pathology confirmed this patient's rash was due to anticonvulsant hypersensitivity syndrome. A rare finding with a prevalence of 1 in 1,000 to 10,000 exposures.³ This syndrome usually occurs 1-4 weeks after exposure to one of the aforementioned aromatic antiepileptic drugs.⁴ What makes our case so unique is the 26 year latent period between administration and reaction. It is hypothesized this disorder is related to an autosomal dominant deficiency of epoxide hydrolase.⁵ Aromatic anticonvulsants, such as phenytoin, are metabolized by the P450 system.³ This can yield a toxic intermediate, which can result in cellular apoptosis or mutations - leading to an immunologic response. One possible explanation is as our patient aged, her ability to metabolize Phenytoin decreased, leading to a buildup of the toxic arene oxide intermediate. Phenytoin has been shown to have decreased hepatic clearance in aging adults.⁷ This highlights the need for continued awareness of potential need for antiepileptic dose monitoring in the elderly.

Due to the acute decompensation of patient's condition and skin condition with unknown etiology, patient was admitted for continued observation in stable condition. Two punch biopsies were performed, one from her left deltoid and another from her right thigh for confirmation of suspected drug-induced skin changes. These were interpreted by Pathology as "The perivascular lymphocytic infiltrate and inflammatory changes are suggestive of an erythema multiformelike eruption/Stevens Johnson syndrome. There is a long-term history of the patient taking Dilantin. The findings are consistent with Dilantin hypersensitivity syndrome. Shared decision making resulted in patient discontinuing all prescribed medications. She was empirically treated for a drug induced hypersensitivity reaction with 60mg of Prednisone daily and discharged in stable condition with close outpatient follow-up

Proposed mechanism of action of aromatic anticonvulsant metabolism and production of toxic arene oxide metabolites.⁶ Individuals susceptible to anticonvulsant hypersensitivity syndrome may have decreased levels of epoxide hydrolase, the enzyme required for detoxification.³ Modified from Knowles et

| 1. | Ghann |
|----|---------|
| | pheny |
| | and M |
| 2. | Shivan |
| | Interno |
| | 10.182 |
| 3. | Knowl |
| | preven |
| 4. | Verrot |
| | childre |
| 5. | Bessm |
| | aware |
| 6. | Lemm |
| | Emerg |
| 7. | Butler. |
| | vol 47 |



Discussion



REFERENCES

nam M, Mansour S, Nabulsi A, Abdoh Q. Anticonvulsant hypersensitivity syndrome after toin administration in an adolescent patient: a case report and review of literature. *Clinical Iolecular Allergy*. 2017;15(1). doi:10.1186/s12948-017-0069-0

nurthy S, Manchukonda R. Carbamazepine induced anticonvulsant hypersensitivity syndrome. ational Journal of Basic and Clinical Pharmacology. 2015:1037-1039. doi:

203/2319-2003.ijbcp20150891.

es S.R., Shapiro L.E., and Shear N.H.: Anticonvulsant hypersensitiviy syndrome: incidence, ntion and management. Drug Saf 1999; 21: pp. 489-501h

tti A., Trotta D., Salladini C., and Chiarelli F.: Anticonvulsant hypersensitivity syndrome in en: incidence, prevention and management. CNS Drugs 2002; 16: pp. 197-205

nertny O., and Pham T.: Antiepileptic hypersensitivity syndrome: clinicians beware and be Curr Allergy Asthma Rep 2002; 2: pp. 34-39

ne, K. A., & Seupaul, awle A. (2007). Anticonvulsant Hypersensitivity Syndrome. Journal of gency Medicine, 33(2), 195–196.

JM, Begg EJ. Free drug metabolic clearance in elderly people, Clinical Pharmacokinet, 2008, vol. 47 (pg. 297-321)